Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.

You may also be interested in...



Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health

Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.

Will Palatin's Phase III Female Sex Endpoint Swap Pass With FDA?

Palatin plans to file the drug for FDA approval in the second half of 2017, but a change in the co-primary endpoint presents a complication.

FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs

Draft guidance says 'associated distress' may replace number of satisfying sexual events as a co-primary efficacy endpoint.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS005623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel